



(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/IB2019/056932

(22) International Filing Date:
15 August 2019 (15.08.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/765,289 20 August 2018 (20.08.2018) US
62/750,393 25 October 2018 (25.10.2018) US
62/750,479 25 October 2018 (25.10.2018) US
62/881,064 31 July 2019 (31.07.2019) US

(71) Applicant: **PFIZER INC.**, [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).

(72) Inventors: **BEAUMONT, Kevin Charles**; c/o Pfizer Inc.,
610 Main Street, Cambridge, Massachusetts 02139 (US).
BREEN, Danna M.; c/o Pfizer Inc., 610 Main Street,
Cambridge, Massachusetts 02139 (US). **CHABOT, Jef-**
frey Raymond; c/o Pfizer Inc., 610 Main Street, Cam-
bridge, Massachusetts 02139 (US). **HE, Tao**; 51 Canter-

bury Hill Road, Acton, Massachusetts 01720 (US). **SH-**
CHORS, Ksenya; 1306 Ashwood Ct., San Mateo, Califor-
nia 94402 (US). **APGAR, James R.**; c/o Pfizer Inc., 610
Main Street, Cambridge, Massachusetts 02139 (US). **LAM-**
BERT, Matthew Allister; c/o Pfizer Ireland Pharmaceuti-
cals, Grange Castle Business Park, Clondalkin, Dublin, 22
(IE).


(74) Agent: **ZIELINSKI, Bryan C.**; PFIZER INC., 235 East
42nd Street, MS 235/9/S20, New York, New York 10017
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

(54) Title: ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE

FIG. 5



(57) Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to GDF15, as well as methods and uses for the antibodies.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*